meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced OC (mOC) - 1st line (L1)
1
mOC - L1 - all population
1
mOC - L1 - PDL1 positive
1
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus SoC
versus all
vs chemotherapy
vs Standard of Care (SoC)
vs placebo plus SoC
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
deaths (OS)
objective responses (ORR)
progression or deaths (PFS)
deaths (OS)
mOC - L1 - PDL1 positive
metastatic/advanced OC (mOC) - 1st line (L1)
mOC - L1 - PDL1 positive
versus placebo plus SoC
atezolizumab plus SoC vs. placebo plus SoC
1
certainty unassessable
-2%
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open